Work

Safety, Tolerability, and Efficacy of Axatilimab, a Colony-stimulating Factor 1 Receptor (CSF-1R) Humanized Antibody, in Advanced Chronic Graft-versus-host Disease-related Bronchiolitis Obliterans Syndrome

Year: 2023

Type: conference-abstract

DOI: 10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a6206

Authors: V. Radojcic, C.L. Kitko, A. Di Stasi, M. Arora, M. Abu Zaid, M.L. Meyers, P. Ordentlich, T. O’Toole, Y. Huang, B.R. Blazar, T.P. Wang, A. Salhotra, I. Pusic, S.J. Lee, Z. DeFilipp

Institutions: Syndax Pharmaceuticals (United States), Vanderbilt University Medical Center, University of Alabama at Birmingham, Masonic Cancer Center, Indiana University Health, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University, University of Minnesota, University of Miami, Sylvester Comprehensive Cancer Center, City Of Hope National Medical Center, Washington University in St. Louis, Fred Hutch Cancer Center, Massachusetts General Hospital

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4367601208

Cites:

Cited by:

Related to: 10